Ferring achieved record sales driven by Reproductive Medicine combined with the emergence of Adstiladrin

Contributed by: Business Wire

Logo

Tags

Research

Genetics

Biotechnology

Other Health

Health

Pharmaceutical

Other Science

Science

Oncology

Ferring Pharmaceuticals

More Like This

Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility

Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring

PR Newswire associated0

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

PR Newswire associated0

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products

PR Newswire associated0

Norgine strengthens rare disease portfolio with acquisition of Theravia

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

PR Newswire associated0

Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meeting and Exposition